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Proliferation, a key feature of cancer cells, accounts for the majority of cancer-
related diseases resulting in mortality. MicroRNAs (miRNAs) plays important post-
transcriptional modulation roles by acting on multiple signaling pathways, but the
underlying mechanism in proliferation and tumorigenicity is unclear. Here, we identified
the role of miR-150 in proliferation and tumorigenicity in leukemia stem cells (LSCs;
CD34+CD38− cells). miR-150 expression was significantly down-regulated in LSCs
from leukemia cell lines and clinical samples. Functional assays demonstrated that
increased miR-150 expression inhibited proliferation and clonal and clonogenic growth,
enhanced chemosensitivity, and attenuated tumorigenic activity of LSCs in vitro.
Transplantation animal studies revealed that miR-150 overexpression progressively
abrogates tumor growth. Immunohistochemistry assays demonstrated that miR-150
overexpression enhanced caspase-3 level and reduced Ki-67 level. Moreover, luciferase
reporter assays indicated Nanog is a direct and functional target of miR-150. Nanog
silencing using small interfering RNA recapitulated anti-proliferation and tumorigenicity
inhibition effects. Furthermore, miR-150 directly down-regulated the expression of
other cancer stem cell factors including Notch2 and CTNNB1. These results provide
insights into the specific biological behavior of miR-150 in regulating LSC proliferation
and tumorigenicity. Targeting this miR-150/Nanog axis would be a helpful therapeutic
strategy to treat acute myeloid leukemia.
Keywords: miR-150, proliferation, tumorigenicity, Nanog, leukemia stem cells
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; LSCs,
leukemia stem cells; MDS, myelodysplastic syndrome; MLL, mixed lineage leukemia.
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INTRODUCTION
Acute myeloid leukemia is a malignant haematologic disease
characterized by an aberrant accumulation of immature myeloid
cells. Although progress has been made, several important
issues remain, including resistance and disease relapse. Evidence
demonstrates that AML is organized as a hierarchy of
several distinct leukaemic blasts with different self-renewal and
differentiation potentials (Bonnet and Dick, 1997). Studies from
clinical data and experimental systems have shown that AML
originates from a rare population of LSCs (CD34+CD38−
cells) or leukemia-initiating cells (LICs) which are capable of
self-renewal, proliferation, and differentiation into malignant
blasts (Lapidot et al., 1994; Bonnet and Dick, 1997; Roboz and
Guzman, 2009). LSCs share some antigenic features with normal
haematopoetic stem cells (HSCs), such as CD34+, CD38−,
CD71−, and HLA-DR−, but can be phenotypically distinguished
from HSCs by disparate markers (Lapidot et al., 1994; Blair et al.,
1997, 1998; Bonnet and Dick, 1997; Jordan et al., 2000). These
cells are responsible for therapeutic resistance and are drivers
of disease progression and relapse (Jordan et al., 2006; Ishikawa
et al., 2007). Recent studies have demonstrated that several solid
tumors are heterogeneous cell populations and are maintained
by cancer stem cells (CSCs) with higher tumorigenic potential
(Ginestier et al., 2007; Chiou et al., 2010; Choi et al., 2012; Du
et al., 2013; Boumahdi et al., 2014). Consequently, it is reasonable
that targeting CSCs is essential for cancer disease treatment.
miRNAs are conserved non-coding RNAs of 18–25
nucleotides in length that suppress gene expression at the post-
transcriptional level by blocking mRNA translation or degrading
target mRNAs through its binding to the 3′-untranslated
regions (3′-UTRs) of target genes (Bartel, 2004). Mounting
evidence has shown that the abnormal expression of miRNAs
or mutations correlates with various human cancers and have
been identified as unique signatures associated with diagnosis,
staging, prognosis, and response to treatment (Esquela-Kerscher
and Slack, 2006; Wang et al., 2015). In addition, miRNAs
function as tumor suppressors and oncogenes (Esquela-Kerscher
and Slack, 2006). Recently, emerging evidence suggests that
miR-150 functions as a major regulator in determining the
fate of haematopoietic stem/progenitor cells in both lymphoid
and myeloid lineages (He Y. et al., 2014). For examples,
downregulation of miR-150 is observed in CML, AML, and
lymphoma, whereas its upregulation has been reported in MDS
and CLL (Fulci et al., 2007; Agirre et al., 2008; Hussein et al.,
2010; Zhao et al., 2010; Fayyad-Kazan et al., 2013). The critical
tumor suppressor role of miR-150 has been demonstrated in the
pathogenesis of AML, particularly MLL gene-rearranged AML
(Jiang et al., 2012). miR-150 is a critical tumor suppressor and
gatekeeper in leukaemogenesis and its repression is required
for the development of MLL-rearranged AML (Jiang et al.,
2012). Furthermore, functional studies illustrated that miR-150
is also an essential tumor suppressor in lymphoma (Watanabe
et al., 2011). MYB, FLT3, EGR2 are important target genes
of miR-150 in AML and lymphoma (Watanabe et al., 2011;
Jiang et al., 2012; Bousquet et al., 2013). Although miR-150
downregulation expression has been observed in hematopoietic
disease, including CML, AML, CLL, and MDS, its definitive
pathological role remains to be elucidated (He Y. et al., 2014).
In addition, the mechanism underlying the role of miR-150 in
regulating LSC proliferation and tumorigenicity has not been
fully elucidated.
Nanog, a homeodomain protein, is required for the
pluripotency of embryonic stem cells (ESCs) and it, along
with Oct4 and Sox2, forms a core ESC network (Mitsui
et al., 2003; Boyer et al., 2005). In addition, functional
studies provide evidence that Nanog plays a vital role in
malignant disease, correlating with cell proliferation and various
malevolent properties such as clonogenic growth, tumorigenicity,
invasiveness, and therapeutic resistance (Noh et al., 2012; Shan
et al., 2012; Jeter et al., 2015). Clinical studies revealed that
Nanog is overexpressed in a variety of cancers (Zbinden et al.,
2010; Choi et al., 2012; Noh et al., 2012; Shan et al., 2012; Jeter
et al., 2015). Moreover, Nanog was found to be highly expressed
in oesophageal cancer tissues and was positively correlated with
histological grade and lymphatic metastases (Yang et al., 2012).
According to Yang’s studies, Nanog could promote tumor cell
proliferation, invasion, and resistance (Yang et al., 2012). In
addition, Eberle et al. (2010) provided evidence that Nanog is
expressed in AML cells (Eberle et al., 2010). These studies are
important and form the base of this study.
In this study, we investigated the biological function and
role, and the underlying molecular mechanism of miR-150 in
LSC proliferation and tumorigenicity. We identified significant
downregulation of miR-150. Furthermore, enhanced expression
of miR-150 potently inhibited proliferation and promoted
apoptosis in vitro and in vivo. In addition, Nanog has been
identified as a functional and direct target of miR-150. We
further demonstrated that si-Nanog, using small interfering RNA
(siRNA), recapitulated the effect of miR-150 on proliferation
inhibition. Finally, we confirmed that miR-150 downregulated
other key factors, including Notch2 and CTNNB1.
MATERIALS AND METHODS
Cell Culture
KG-1a and MOLM13 cell lines were obtained from the
Laboratory Animal Center of Sun Yat-sen University. The cells
were cultured in RPMI 1640 medium supplemented with 10%
FBS and 1% penicillin-streptomycin at 37◦C in 5% CO2. KG-
1a-LSCs (CD34+CD38−) and MOLM13-LSCs (CD34+CD38−)
were isolated using magnetic microbeads (Miltenyi Biotec,
Germany) and the purity of LSCs was 93.58% as described in our
previous study (Zhang et al., 2015). Human leukemia samples
were collected in the First Affiliated Hospital of Guangdong
Traditional Medicine University (FAHGTMU). All the materials
were obtained with written informed consent, and the procedures
were approved by the FAHGTMU and the Ethical Committee of
Jinan University.
qPCR Analysis and miRNA Detection
The total mRNAs were extracted using Trizol (Invitrogen, USA)
and were reverse-transcribed using a Bio-Rad system. qPCR was
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performed on a Bio-Rad system using Taqman for mRNAs and
miRNAs. Expression of miR-150 was analyzed using the SsoFast
EvaGreen Supermix miRNA detection Kit (Bio-Rad, CA). U6
expression was used as an internal control. miR-150 expression
in each sample was calculated by normalizing with U6 and the
relative expression was calculated using 2−11Ct values. mRNA
expression level in Nanog, Notch2, Hsp90B1 and CTNNB1 were
analyzed by the primers described in Supplementary Table S1.
β-actin was used as an internal control. These stemness genes
expression level were calculated using 2−11Ct values. All the
experiments were done in triplicate. A t-test was used to evaluate
the differences of miR-150 and those stemness genes expression
levels among two groups. A P value of < 0.05 was considered
significant. SPSS 19.0 was employed to calculate the difference.
Western Blot Analysis
Cells were lysed and the protein concentration was determined
using BCA assay (Beyotime Biotechnology, China). The protein
were subjected to polyacrylamide gel electrophoresis. Then,
the proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane (Millipore, USA). The membrane was
blocked with blocking buffer [0.1% Tween-20 in 5% skimmed
milk (Gibco, USA)] for 1.5 h. The membrane was incubated
with a primary antibody [Nanog, Cell Signaling Technology
(CST), #3580; β-catenin, CST, #9582; Hsp90B1, CST, #20292;
Notch2, abcam, ab#8927] at 4◦C overnight. Next, the membrane
was washed with 0.1% Tween-20 Tris-buffered saline. Then,
the membrane was incubated with horseradish peroxidase-
conjugated secondary antibodies for 1.5 h at room temperature.
The bound antibodies were detected using a chemiluminescence
detection kit ECL (Millipore, USA). β-actin was used as an
internal control.
Soft Agar and Sphere Formation Assay
For the soft agar assay, 1 × 103 LSCs were mixed with 0.3%
low melting agar in IMDM medium (Stem Cell Technologies)
supplemented with 10% FBS and plated on a 0.6% low
melting agar-coated 6-well plate. The plates were incubated
at 37◦C in a humidified incubator for 15 days. Every well
was stained with 0.2 ml 0.05% crystal violet for 0.5 h at
37◦C. The numbers of positive colonies (>8 cells/colony)
were counted. The experiments were performed at least three
times.
Flow Cytometry and Annexin
V-APC/7-AAD Staining
For the apoptosis assay, cells were transfected with miR-150, miR-
NC, si-Nanog, or si-NC for 48 h. They were then harvested and
5 µl of binding reagent and 5 µl of Annexin V-APC (KeyGen
BioTech, China) were added. After 30 min, cells were washed
three times with PBS and stained with 5 µl of 7-AAD (KeyGen
BioTech, China) for 15 min at room temperature according to the
manufacturer’s instructions. The detailed steps were guided by
the manufacturer’s instructions. The experiments were repeated
three times. All data were analyzed and calculated using FlowJo
software.
Luciferase Reporter Assay
The dual-luciferase reporter assay (Promega) was employed to
evaluate the interaction between miR-150 and the 3′-UTR of
Nanog. The sequences of the Nanog 3′-UTR and the mutant
Nanog 3′-UTR were cloned into the luciferase reporter pGL4.11.
In addition, miR-150 was cloned into an miRNA expression
lentivial vector (Genepharma, China). LSCs (1 × 105 cells/well)
were cultured in 24-well plates, transfected with Nanog 3′-UTR
and the mutant 3′-UTR of Nanog and either miR-150 or a
negative control (NC) using Lipofectamine 2000 (Invitrogen,
USA) according to the manufacturer’s protocol. Luciferase
activity was measured 48 h after transfection using the Dual
Luciferase Reporter Assay System (Beyotime Biotechnology,
Haimen, China) and was normalized to Renilla luciferase activity.
Wild-type and mutant sequence of Nanog 3′-UTR are seen in
Supplementary Table S1.
miRNA Mimic and Inhibition and shRNA
Lentiviral Vector Construction
To knockdown the expression of Nanog in LSCs, the Nanog-
specific si-Nanog1 and si-Nanog2 was synthesized (Genepharma,
China) according to the study of Kyung Hee Noh (Noh
et al., 2012). The LSCs were transfected with si-Nanog1
and siNanog2 and siRNA-NC (Genepharma, China) mixed
with Lipofectamine 2000 (Invitrogen, USA) according to the
manufacturer’s instructions. After transfection for 72 h, total
protein and RNAs were prepared from the cells and were
subjected to western blot analysis and qPCR, respectively. The
sequence of si-Nanog1 and si-Nanog2 and siRNA-NC are seen
in Supplementary Table S1. In addition, miR-150 lentiviral
vector was constructed by Genepharma. The transfections were
conducted according to the manufacturer’s protocol. miR-150
sponge and Nanog vector (pcDNA3.1-Nanog) was purchased
from Genepharma (Shanghai, China).
Proliferation Analysis
Leukemia stem cell proliferation analysis was conducted with
trypan blue (Beyotime, Haimen, China). LSCs were seeded into
a 48-well plate containing 100 µl of medium. Subsequently, the
48-well plate was incubated for 4 h at 37◦C in 5% CO2 in a
humidified incubator. The LSCs were counted by trypan blue.
For Ki-67 cell proliferation detection, 1.0× 105 transfected LSCs
were used to complete the experiments. The cells were incubated
with an antibody (Cell Signaling Technology) against Ki-67 and
were washed three times with Tris-buffered containing 0.1%
Tween-20. Then, the cells were incubated with FITC-conjugated
goat secondary antibody for 0.5 h. The cells were photographed
by a fluorescence microscope (Zeiss, Germany). The data are
presented as the mean ± standard deviation (SD) from three
independently repeated experiments.
Animal Models and
Immunohistochemistry (IHC)
BALB/c and nonobese diabetic/severe combined immuno
deficient (NOD/SCID) mice were housed and bred in specific
pathogen-free conditions. All procedures involving animals were
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approved by the experimental animal center of Jinan University
and the Ethical Committee of Jinan University. All animal
experiments protocol were conducted according to the animal
care ethical guidelines of the Review Committee for the Use of
Human or Animal Subjects of Jinan University.
For the subcutaneous model, six 5-week-old female BALB/c
mice (HFK Bioscience, Beijing, China) were subcutaneously
injected in the neck flank with 2.0× 105 LSCs in which lentiviral
vectors containing miR-150 or NC were transfected. The LSCs
were mixed with Matrigel (Corning, USA) at the ratio of 1:2.
The tumor size was measured every 3 days, and the tumor
volume was calculated as L × W2 × 0.5 (mm3; L indicates
length, and W indicates width). Four weeks later, the mice
were euthanized, the tumors were harvested and the weight of
tumors was measured. The tumors were embedded in paraffin.
Slides were pre-treated with citrate buffer (pH 6.0). For blocking
endogenous peroxidase activity, the slides were treated for 15 min
with methanol containing 0.3% H2O2. After washing in Tris
buffer, the slides were incubated with anti-human Caspase-3
primary antibody (goat polyclonal, diluted 1:200; Abcam, USA)
and anti-Ki-67 primary antibody (mouse polyclonal, diluted
1:200, Cell Signaling Technology, USA). For immunostaining,
a peroxidase-conjugated antibody was used. IHC was done as
described previously (Ferretti et al., 2012).
For malignant hematologic tumor model, four 5-week-old
female NOD/SCID mice (n = 4) were intravenously injected
via the tail vein with 2 × 105 LSCs in which miR-150 was
overexpressed by lentiviral vector with GFP tag. In the NC group
(n = 4), mice were intravenously injected via the tail vein with
2 × 105 LSCs transduced with NC lentiviral vectors. In vivo
imaging experiments was completed (Xtreme, Germany) and
mice were euthanized after 60 days, the spleens were collected.
Human CD45+ (hCD45+) leukemia cells from mice spleen
were evaluated by flow cytometry (FACS Calibur, BD Company).
Human leukemia cells were identified as CD45+ cells.
Statistical Analysis
Statistical analysis was performed using SPSS 19.0. The
experiments were repeated at least three times. The results
were presented as the mean ± SD. A two-tailed Student’s
t-test was used for statistical analysis. Two-way ANOVA was
used to determine statistical differences for in vivo experiments.
∗P < 0.05 and ∗∗P < 0.01 were considered statistically significant
in all cases.
RESULTS
Overexpression of miR-150 Inhibits LSC
Proliferation In vitro
The miR-150 expression level was reported to be downregulated
in leukemia (Fulci et al., 2007; Hussein et al., 2010). To investigate
its expression condition and biological function, we collected
blood samples from 19 AML patients and 11 healthy subjects
and then isolated CD34+/CD34− cells (Supplementary Table
S2). Consistent with previous studies, on quantification of miR-
150 mRNA expression levels using qPCR, we found that the
miR-150 level was significantly lower in CD34+ cells than in
CD34− cells in patients and normal blood cells (Figure 1A).
Furthermore, miR-150 expression was downregulated in KG-
1a-LSCs (CD34+CD38−) and MOLM13-LSCs (CD34+CD38−)
compared with that in normal blood cells (Figure 1B). To further
confirm its low expression level in leukemia, another two AML
clinical samples were collected. Consistently, miR-150 levels
were still found to be lower in these two samples (Figure 1B).
These observations promoted us to investigate its biological
function by performing gain-of-function studies. To this end,
LSCs isolated form KG-1a and MOLM13 were transfected with
miR-150 mimic or NC and cell proliferation was analyzed. Cell
transfected with miR-150 (72 h) markedly increased miR-150
levels (Supplementary Figure S1). As expected, the proliferation
of LSCs transfected with miR-150 was remarkably suppressed
compared with that of LSCs transfected with NC (Figures 1C,D).
On the contrary, miR-150 sponge increased the proliferation
effect on LSCs (Figures 1C,D). Then, cell viability was evaluated
using 5 µM cytarabine (Ara-C), a drug for AML treatment
according to our previous studies (Zhang et al., 2015). Cell
viability was more inhibited after transfection with miR-150
compared with that with NC after the addition of Ara-C
(Figure 1E). However, the viability of LSCs transfected miR-150
sponge was increased (Figure 1E). These studies demonstrate
that miR-150 recovery inhibits LSCs proliferation.
To explore the effect of miR-150 on the proliferation
of CD34+CD38− cells, we used CD34-PE and CD38-FITC
antibodies to stain the KG-1a-LSCs after transfection of miR-
150 or NC and performed flow cytometry analysis. As shown in
Figure 1F, the percentage of CD34+CD38− cells was decreased
significantly in miR-150-transfected cells (1.4%) compared
with the NC group (96.8%; Figure 1F). To further confirm
the inhibiting effects of miR-150 on proliferation, apoptosis
experiments were performed. Flow cytometry assays showed
that the apoptosis rate increased remarkably in KG-1a-LSCs
transfected with miR-150 compared to those transfected with
NC (34.71% vs. 8.96%, Figure 1G). miR-150 sponge increased
the proliferation (Figure 1G). Similarly, miR-150 overexpression
inhibited MOLM13-LSCs survival (32.63% vs. 9.31%, Figure 1G)
and miR-150 sponge increased the proliferation (Figure 1G).
These results suggest that miR-150 suppresses LSCs proliferation.
miR-150 Overexpression Impairs LSC
Clonogenic and Sphere Formation
Activities
The immunofluorescence assay demonstrated that miR-150
inhibited KG-1a-LSC proliferation according to the expression of
Ki-67 (Figure 2A). Similarly, the inhibited effect was observed in
MOLM13-LSCs (Figure 2B). But miR-150 sponge increased Ki-
67 expression level (Figures 2A,B). The ability to form spheroids
in soft agar plate is a property of CSCs. To investigate whether
miR-150 regulates clonogenic and sphere formation ability, LSCs
were transfected with miR-150 and a soft agar assay was used
to assess the regulation of LSCs by miR-150. Our findings
demonstrated that miR-150 overexpression greatly decreased, but
its inhibition increased, the number of both types LSCs from
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FIGURE 1 | miR-150 is upregulated in LSCs and plays an essential role in regulating proliferation. (A) qPCR analysis of miR-150 in normal blood and
paired CD34+/CD34− cells in clinical samples from AML patients. CD34+ cells were isolated using magnetic microbeads. (B) qPCR analysis of miR-150 in another
AML patient and LSCs from leukemia cell lines KG-1a and MOLM13. U6 was referenced as a control. (C,D) Proliferation analysis of LSCs after miR-150 and NC
transfection. 5000 cells were transfected with miR-150 and seeded into 48-well plates. They were cultured at 37◦C. The proliferation LSCs was counnted by trypan
blue. (E) Cell viability analysis of LSCs transfected with miR-150 and NC. LSCs (1.0 × 104 cells/well) were seeded into 96-wells plates and Ara-C was added. Cells
were incubated for 48 h. The readings were recorded by a microplate absorbance reader. (F) Flow cytometery analysis percentage of KG-1a-LSCs after they were
transduced with miR-150 mimic. (G) Flow cytometry apoptosis analysis of LSCs transfected with miR-150, miR-150 sponge and NC. ∗P values of < 0.05 and ∗∗P
values of < 0.01 were considered statistically significant. The experiments were repeated three times independently (mean ± SD). NC, negative control.
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FIGURE 2 | miR-150 overexpression suppresses LSC clonogenic growth, and sphere-forming capacities. (A,B) Proliferation analysis of LSCs transfected
with miR-150 or NC. Transfected LSCs (1.0 × 105 cells) were used to complete the experiments. Cells were incubated with antibody against Ki-67. Cells were
washed three times with Tris-buffer containing 0.1% Tween-20. Then, the cells were incubated with goat secondary antibody. Scale bars: 40 µm. (C) Soft agar plate
experiments were used to test the LSCs proliferation capacities. 1 × 103 LSCs transduced with either miR-150, miR-150 sponge and NC were seeded into a 6-well
soft agar plate and cultured for 14 days. The cells were stained with 0.05% crystal violet for 0.5 h at 37◦C. Representative micrographs are shown. All data represent
the mean ± SD from three independent experiments (∗P < 0.05). In all experiments, data represent the mean ± SD from three independent experiments
(∗P < 0.05). Scale bars: 10 mm.
KG-1a and MOLM13 compared with the NC (Figure 2C). In
conclusion, these findings revealed that miR-150 overexpression
impairs the clonogenic and sphere formation activities.
miR-150 Overexpression Suppresses
Xenograft Tumor Growth In vivo
To further help elucidating the suppressed effect of miR-150, we
assessed the impact of miR-150 on KG-1a and MOLM13 LSCs
in vivo. The lentiviral vector encoding miR-150-transduced LSCs
from KG-1a were implanted subcutaneously into BALB/c mice,
and observations and measurements were recorded 28 days after
injection. Strikingly, tumor regeneration was notably inhibited
in every case (Figure 3A, Left), and tumor growth was severely
delayed (Figure 3A, right). Consistent with LSC-enriched KG-1a
cells, these findings were also observed in MOLM13-LSCs. The
findings demonstrated that miR-150 overexpression significantly
suppressed tumor growth (Figure 3B, left). Moreover, in
comparison with the control groups, the weight of the tumors
in the group treated with miR-150 were smaller than NC group
(Figure 3B, right). To further explore the biological role of miR-
150, the immunohistochemical staining of Ki-67 and activation
of caspase-3 in the tumors was performed. The results revealed
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FIGURE 3 | miR-150 overexpression impairs the tumorigenicity of LSCs. (A,B) Xenograft tumors volume derived from miR-150 and NC lentiviral vectors (Left).
LSCs (2.0 × 105) were transduced with miR-150 or NC. Tumors volume were weighed and photographed after 30 days (Right; mean ± SD, ∗P < 0.05). (C,D)
Immunohistochemistry analysis of tumor growth. Ki-67 and Casp-3 were detected. Error bars represent the mean ± SD from three independent experiments. Scale
bars: 40 µm. (E) By experimental proliferation and tumorigenicity assay in NOD/SCID mice which were evaluated by fluorescence imaging, flow cytometery analysis
demonstrated that miR-150 inhibited LSCs proliferation, whereas NC did not (n = 4).
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that the expression of caspase-3 was increased in the miR-
150 overexpression tumor group (Figures 3C,D). Meanwhile,
decreased Ki-67 expression was observed in miR-150-transduced
tumor (Figures 3C,D). The in vivo role of miR-150 was evaluated
by NOD/SCID mice. According to other studies (Guzman et al.,
2002; Lumkul et al., 2002), the percenatage of human CD45+
(hCD45+) cells was analyzed by flow cytometry. The percentage
of hCD45+ cells in mice spleen was significantly less than the NC
group (4.5% vs. 42%; Figure 3E). These results implicated that
miR-150 inhibited the LSCs proliferation and the tumorigenicity
from KG-1a.
Nanog Is a Functional Target of miR-150
To determine the molecular mechanism by which miR-
150 exerts its tumor suppressing properties, we employed 3
algorithms to predict the potential miRNA targets of miR-
150, including Targetscan, miRBase, and microRNA.org. These
different computational methods identified many candidate
genes that were commonly predicted to be possible targets of
miR-150. To further narrow the possible downstream effectors
of miR-150, Gene Ontology Analysis was carried out. Several
stemness genes were found, including Nanog, CTNNB1 coding
protein β-catenin, Notch2, and Hsp90B1 (Figure 4A). As known,
these genes play a critical role in CSCs. We were particularly
interested in Nanog because Nanog is critical for ESCs and CSCs
(Mitsui et al., 2003; Zbinden et al., 2010; Choi et al., 2012; Shan
et al., 2012). In addition, analysis of the 3′-UTR of Nanog showed
that it is highly conserved among different species (Figure 4B).
We found that Nanog is expressed in KG-1a-LSCs and
MOLM13-LSCs (Figure 4C). This is consistent with Eberle’s
studies (Eberle et al., 2010). To assess whether Nanog is a target
of miR-150, we again transfected miR-150 into both of the LSCs
and examined Nanog protein and mRNA expression levels. As
shown in Figure 4D, the mRNA levels of Nanog in the LSCs
were sharply decreased compared with those of NC (P < 0.05).
Consistently, the protein level of Nanog was significantly reduced
after transfection with miR-150 (Figure 4E). To determine
whether Nanog is a direct and functional target of miR-150, we
engineered 3′-UTR fragments, in which wild-type and mutant
binding sites were inserted into the region downstream of
the luciferase reporter gene (Figure 4F). Luciferase reporter
assays showed that miR-150 transfection caused a notable
decrease in relative luciferase activity in LSCs when the Nanog
plasmid containing a wild-type 3′-UTR was present (Figure 4G).
However, the luciferase activity in the 3′-UTR of the mutant
binding site did not decrease significantly (Figure 4G). These
results provided evidence suggested that Nanog is a target of
miR-150.
Downregulation of Nanog Inhibits LSCs
Proliferation
Next, we investigated whether the downregulation of Nanog
inhibits LSC proliferation. To this end, both types of LSCs
were infected with siRNA mimics against Nanog or siRNA-
NC and Nanog was overexpressed. Western blot analysis
demonstrated that the expression level of Nanog was effectively
reduced by si-Nanog1 and si-Nanog2 (Figure 5A). miR-
150 decreased Nanog expression level while Nanog vector
increased its level (Figure 5A). To further explore whether
silencing of Nanog had an impact on the proliferation of LSCs,
trypan blue staining was used to evaluate LSCs proliferation.
Our findings showed that the proliferation of LSCs from
KG-1a and MOLM13 were suppressed after si-Nanog1 and
si-Nanog2 transfecction (Figures 5B,C). Meanwhile, miR-
150 overexpression suppressed the LSCs proliferation, which
was reversed by Nanog overexpression (Figures 5B,C). Flow
cytometry analysis demonstrated that si-Nanog1 or si-Nanog2
transfection inhibited the LSCs proliferation and promoted it
apoptosis, compared with those transfected with siRNA-NC
(Figure 5D). In addition, miR-150 overexpression increased
LSCs apoptosis, which was reversed by Nanog overexpression
(Figure 5D). Consistently, soft agar colony formation assays
indicated that si-Nanog1 and si-Nanog2 significantly reduced
the colonies efficiency and number of both types of LSCs
(Figure 5E). miR-150 overexpression inhibited, but Nanog
overexpression increased, the colonies number (Figure 5E).
Collectively, silencing of Nanog using siRNA suppressed LSC
proliferation and depletion of Nanog recapitulated the function
of miR-150. The effect of miR-150 on LSCs proliferation was
reversed by Nanog overexpression. These results confirmed that
Nanog is a direct and functional target of miR-150.
miR-150 Targets Several Stem Cell
Regulatory Factors
To further elucidate the molecular mechanism by which miR-
150 regulates the proliferation of LSCs (Figure 4A), we tested
the expression levels of genes including Notch2, Hsp90B1, and
CTNNB1, besides Nanog (Zbinden et al., 2010; Liu et al., 2015;
Zhu et al., 2015; White et al., 2016), which are known oncogenic
and stem cell regulators that are implicated in leukemia initiation
and progression. According to computational findings, they are
targets of miR-150 (Figure 6A). The findings suggested that
miR-150 overexpression decreased the mRNA levels of different
molecules in a cell type-dependent manner. In KG-1a-LSCs, miR-
150 significantly reduced Nanog and CTNNB1 levels (Figure 6B),
whereas in MOLM13-LSCs, miR-150 additionally attenuated
Nanog and Notch2 levels (Figure 6C). In sharp contrast, the
level of Hsp90B1 remained unchanged in both types of LSCs
(β-actin was used as an internal control, Figures 6B,C). Western
blot analysis of Nanog, Notch2, β-catenin, and Hsp90B1 were
consistent with the results of qPCR. As expected, Nanog levels
were reduced by miR-150 overexpression in both types of LSCs,
with a decrease from 50 to 80% compared with that in NC-
transfected cells (P< 0.05, Figures 6D,E). The β-catenin level was
sharply reduced after being transfected with miR-150, compared
with transfection with NC, in KG-1a-LSCs (Figure 6D), while its
expression level did not change in MOLM13-LSCs (Figure 6E).
On the contrary, the Notch2 level did not change in KG-1a-
LSCs after the overexpression of miR-150, but its expression
level was remarkably reduced after being transfected with miR-
150 compared to those transfected with NC (Figures 6D,E).
Hsp90B1 protein levels remained unchanged in both types of
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FIGURE 4 | Nanog is a direct target of miR-150. (A) Diagram analysis of miR-150 target genes predicted by three microRNA research databases. The target
genes contain stemness genes. (B) Schematic diagram displaying the evolutionarily conservative sites of 3′-UTR targeted by miR-150 among different species.
(C) Western blot analysis of Nanog in LSCs. β-actin was a loading control. (D,E) Nanog mRNA levels and protein expression levels, analyzed by western blot and
qPCR 48 h after transfection. β-actin was used as an internal control (∗P < 0.05). (F) Schematic diagram of the Nanog 3′-UTR constructs and the alignment of
wild-type (WT) and mutant type (Mut) miR-150 putative target sites in the 3′-UTR of Nanog. (G) LSCs were co-transfected with an empty vector (Ctrl), or a wild-type
or mutant target site of the Nanog 3′-UTR vector, as well as a miR-150 vector. Luciferase activity was normalized to Renilla activity and presented as relative to
miR-NC (∗P < 0.05). Data for each condition are shown from three independent experiments (mean ± SD).
LSCs transfected with or without miR-150 (Figures 6D,E). Taken
together, these results suggest that miR-150 has a regulating effect
on Nanog, Notch2, and CTNNB1 expression level, and is cell
type-dependent.
DISCUSSION
Functional evidence demonstrates that a subpopulation of cancer
cells is responsible for stem-like characteristics, such as self-
renewal and limitless proliferation (Sands et al., 2013). CSCs are
involved in tumor initiation, maintenance, and chemo-resistance
(Ishikawa et al., 2007; Gottschling et al., 2012). Therefore,
clarifying the molecular mechanism underlying the regulation of
CSCs is critical for cancer disease treatment.
Over the past decade, it has been clarified that the
dysregulation of miRNA expression has emerged as an essential
role in leukemia, where they act as either oncogenes or
tumor suppressors (Fabbri et al., 2008; Garzon and Croce,
2008). Accumulating data has demonstrated that miR-150 is
associated with the development of lymphoid and myeloid
lineages in human leukemia progression (He Y. et al., 2014;
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FIGURE 5 | si-Nanog recapitulates the function of miR-150 in LSCs. (A) Western blot analysis of LSCs transduced with si-Nanog1 and si-Nanog2 against
Nanog. β-actin was used as an internal control. (B,C) Proliferation analysis of LSCs transfected with siRNA against Nanog, miR-150 and Nanog vector. LSCs were
transduced with siRNA, miR-150 and Nanog vector seeded into 96-well plates, and incubated for 48 h. The readings were recorded at 450 nm in a microplate
absorbance reader (mean ± SD, ∗P < 0.05). (D) Flow cytometry apoptosis of LSCs transfected with si-Nanog1 and si-Nanog2 against Nanog, miR-150 and Nanog
vector. After 48 h, LSCs were collected and the effects were evaluated by flow cytometry. NC was used as negative control. All the experiments were repeated
independently three times (mean ± SD, ∗P < 0.05, ∗∗P < 0.01). (E) 1 × 103 LSCs were transduced with si-Nanog1, siNanog2 against Nanog, miR-150 and Nanog
vector. The transfected LScs were seeded into 6-well plates containing 0.3% soft agar. They were cultured for 14 days. The colonies were stained with 0.05% crystal
violet for 0.5 h at 37◦C and counted. All data represent the mean ± SD from three independent experiments (∗P < 0.05, ∗∗P < 0.01). Scale bars: 10 mm.
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FIGURE 6 | miR-150 regulates several self-renewal genes in LSCs. (A) Predicted binding targets of miR-150 to the 3′-UTRs of Nanog, Hsp90B1, CTNNB1,
and Notch2. (B,C) qPCR analysis of miR-150’s effects on the mRNA levels of candidate genes in LSCs. β-actin was used as an internal control and the data shown
are relative to the effects of NC (∗P < 0.05). (D,E) Western blot analysis of miR-150’s effects on the protein levels of Nanog, Hsp90B1, Notch2, and β-catenin
encoded by CTNNB1 in LSCs. Densitometric values relative to NC cells are provided. β-actin was used as a loading control.
Stamatopoulos et al., 2015). However, the relationship between
Nanog and miR-150 has not been elucidated. In this study,
we identified decreased miR-150 expression levels in AML
clinical samples and cell lines. Overexpression of miR-150
significantly reduced proliferation, induced apoptosis, and
attenuated chemo-resistance and spheroid formation in LSCs.
According to in vivo studies, miR-150 overexpression inhibited
the tumorigenicity of LSCs. But we found that although the
effect is not obvious miR-150 overexpression inhibited the
tumorigenicity in LSCs. Maybe the biology role of miR-150
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in vivo is different from that in vitro due to the different
environment. Furthermore, miR-150 regulates the proliferation
and survival of LSCs by modulating Nanog. Nanog was identified
as a direct and functional target of miR-150. Consistently, the
depletion of Nanog using siRNA recapitulated the observation
that miR-150 targets Nanog. Therefore, our study demonstrated
that miR-150 is critical for the proliferation and chemo-resistance
of LSCs and that these effects were meditated by Nanog
expression.
Indeed, the role of miR-150 in human cancer is context-
dependent, as this microRNA functions as either an oncogene
or a tumor suppressor. For example, studies have shown that
the expression level is upregulated in CD19+ B cells from CLL,
whereas its level was observed to be downregulated in CML
and ALL (He Y. et al., 2014; Mraz et al., 2014). Furthermore,
research demonstrated that miR-150 promotes proliferation and
metastasis by targeting the v-src avian sarcoma (Schmidt-Ruppin
A-2) viral oncogene homolog (SRC; Cao et al., 2014). In addition,
in situ hybridisation revealed that the miR-150 expression level
was decreased in breast cancer samples compared to adjacent
normal cells (Huang et al., 2013). Reports by Stamatopoulos have
revealed opposite prognostic significance for cellular and serum
circulating miR-150 in CLL patients (Stamatopoulos et al., 2015).
In our studies, we found that the miR-150 expression level was
significantly decreased in CD34+ cells and LSCs compared with
normal blood.
Additionally, miR-150 is warranted further investigation
for other reasons. Two research groups have independently
reported that the dysregulation of miR-150 expression in murine
hematopoietic stem cells remarkably arrested the development of
B cells at the pro-B-cell stage (Xiao et al., 2007; Zhou et al., 2007).
Bruchova et al. (2007) showed that miR-150 is progressively
downregulated during normal erythropoiesis. However, in 2008,
another study using a novel methodology illustrated that
miR-150 is moderately expressed in megakaryocyte/erythrocyte
precursors and is increased as the cells undergo megakaryocytic
differentiation (Lu et al., 2008). In the present study, miR-150 was
shown to regulate LSC proliferation and chemo-resistance and
inhibit LSC tumorigenicity.
It is of particular interest to elucidate the molecular
mechanism by which miR-150 regulates hematopoietic
malignancies through its target genes. The expression level
of miR-150 was inversely associated with the mRNA level of
MYB in MDS, which implies that MYB might be an important
target of miR-150 (Xiao et al., 2007). In another study, miR-150
directly downregulated the expression of AKT2, reduced levels
of phosphorylated AKTser473/4, and increased levels of tumor
suppressors, such as Bim and p53 (Watanabe et al., 2011). MYB,
FLT3, and EGR2 have been identified as critical target genes
of miR-150 in MLL-rearranged AML, while AKT2 is a direct
target of miR-150 in NK/T-cell lymphoma (Fulci et al., 2007;
Hussein et al., 2010; Watanabe et al., 2011; Jiang et al., 2012; He
Y. et al., 2014). In our study, we found that Nanog is a direct and
functional target of miR-150 in AML.
Nanog is a homeodomain protein that, along with Oct4
and Sox2, plays a role in ESC self-renewal and pluripotency
(Mitsui et al., 2003; Boyer et al., 2005). In our studies, we
found that Nanog is expressed in LSCs, which is consistent
with Eberle’s studies (Eberle et al., 2010). In addition, studies
have illustrated that Nanog2 was found in mixed lymphocytic
leukemia, which suggests that Nanog2 could be involved in the
regulation of leukemic stem cell functions (Eberle et al., 2010).
Nanog plays a key role in CSC proliferation and clonogenic
growth. For example, RNA interference-mediated silencing of
NANOG leads to reduced long-term clonal and clonogenic
growth and proliferation (Jeter et al., 2009). Similarly, the
knockdown of Nanog was associated with a loss of proliferation,
reduced self-renewal, and increased apoptosis via blocking the
cell cycle progression through p53 signaling (Cao et al., 2013).
In our studies, we found that Nanog is a direct and functional
target of miR-150. miR-150 inhibited LSCs proliferation, which
was reversed by Nanog overexpression. In addition, si-Nanog
attenuated the clonogenic growth of the LSCs and promoted LSC
apoptosis.
In addition to Nanog, other stemness genes including Notch2,
CTNNB1 and Hsp90B1 are also important to CSCs and cancer
cells. Notch2+ human pancreatic cancer Bxpc-3 and Panc-1 cells
have properties of CSCs, which have a strong tumourigenic ability
(Zhou et al., 2013). Depletion of CTNNB1 impaired the stem-like
phenotype of renal cell carcinoma (Lin et al., 2015). Indeed, the
WNT/CTNNB1 signaling is involved in regulating many types of
stem cells (He K. et al., 2014). Furthermore, Hsp90B1 is expressed
in various types of cancer cells including breast cancer, human
osteosarcoma, CML and non-small cell lung cancer (Cawthorn
et al., 2012; Li et al., 2012; Mosakhani et al., 2013; Coskunpinar
et al., 2014). Accordingly, in future anti-tumor studies these
stemness genes may be important targets.
CONCLUSION
We have demonstrated that miR-150 is downregulated in LSCs
cell lines and clinical blood samples. miR-150 overexpression
can inhibit LSCs proliferation, attenuate clonal and clonogenic
growth, decrease tumorigenicity, both in vitro and in vivo.
Furthermore, Nanog was identified as a direct and functional
target of miR-150. Silencing of Nanog recapitulated the
anti-proliferation function of miR-150 and attenuated LSCs
clonogenic growth. Our findings demonstrate that the miR-
150/Nanog axis provides new insight into the mechanisms for
eliminating LSCs and the restoration of miR-150 expression may
be a potential therapeutic strategy for the treatment of AML in
the future.
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